187420 — GenoFocus Income Statement
0.000.00%
- KR₩84bn
- KR₩124bn
- KR₩27bn
Annual income statement for GenoFocus, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 14,942 | 18,769 | 25,874 | 27,802 | 27,008 |
Cost of Revenue | |||||
Gross Profit | 3,695 | 6,059 | 9,831 | 10,215 | 7,331 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 19,827 | 27,121 | 29,708 | 34,997 | 26,510 |
Operating Profit | -4,885 | -8,352 | -3,834 | -7,195 | 498 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -5,220 | -12,127 | -14,402 | -11,336 | -787 |
Provision for Income Taxes | |||||
Net Income After Taxes | -5,522 | -12,125 | -8,526 | -13,373 | -722 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -5,757 | -12,217 | -6,817 | -12,968 | -2,950 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -5,757 | -12,217 | -6,817 | -12,968 | -2,950 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -199 | -442 | -301 | -548 | -411 |
Dividends per Share |